The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View aml content recommended for you
Quizartinib monotherapy for relapsed/refractory acute myeloid leukemia
Quizartinib is a small, potent, next-generation FMS-like tyrosine kinase 3 (FLT3) inhibitor in relapsed or refractory acute myeloid leukemia (R/R AML). In a May issue of Lancet Oncology, Jorge Cortes from The University of Texas MD Anderson Cancer Center, Houston, TX, USA, and colleagues published the results of an open-label, multicenter, single-arm, phase II study (NCT00989261) evaluating quizartinib in patients with morphologically documented primary AML or secondary AML.
In total, 333 patients were enrolled between November 2009 and October 2011. Patients were divided into two groups as follows: cohort 1 included 157 patients (age = 60 years or older) with relapsed/refractory (R/R) AML within one year after first-line therapy; cohort 2 included 176 patients (age = 18 years or older) with R/R AML following salvage chemotherapy or hematopoietic stem cell transplantation (HSCT). Quizartinib was administered once daily as an oral solution in 28-day treatment cycles. Patients received quizartinib until relapse, intolerance, or HSCT.
Key findings:
- Complete remission rates in cohort 1:
- Composite complete remission: 63/112 (56%) FLT3-ITD-positive patients and 16/44 (36%) FLT3-ITD-negative patients
- Complete remission: 3/112 (3%) FLT3-ITD-positive patients and 2/44 (5%) FLT3-ITD-negative patients
- Complete remission rates in cohort 2:
- Composite complete remission: 62/136 (46%) FLT3-ITD-positive patients and 12/40 (30%) FLT3-ITD-negative patients
- Complete remission: 5/136 (4%) FLT3-ITD-positive patients and 1/40 FLT3-ITD-negative patient
- ≥ Grade 3 treatment-related treatment-emergent adverse events included febrile neutropenia (23%), anemia (23%), thrombocytopenia (12%), QT interval corrected using QTcF prolongation (10%), neutropenia (9%), leukopenia (7%), decreased platelet count (6%), and pneumonia (5%)
- Serious adverse events included febrile neutropenia (38%), AML progression (22%), pneumonia (12%), QTcF prolongation (10%), sepsis (8%), and pyrexia (5%)
The authors concluded that single-agent quizartinib is safe and efficient in patients with R/R AML, predominantly with FLT3-ITD mutations. The study group added that “these findings confirm that targeting the FLT3-ITD driver mutation with a highly potent and selective FLT3 inhibitor is a promising clinical strategy to help improve clinical outcomes in patients with very few options. Phase 3 studies (NCT02039726; NCT02668653) will examine quizartinib at lower starting doses.”
References
1. Cortes J. et al. Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol. 2018 May 30. DOI: 10.1016/S1470-2045(18)30240-7